Enterprise Value to EBITDA Ratio: Mural Bio (MURA)
Mural Oncology plc (MURA) specializes in developing innovative cancer therapies. High R&D costs and strict FDA oversight create significant barriers to entry, yet progress in immunotherapy serves as a powerful growth driver, as evidenced by market price action with the 0.00 indicator. Primary risks include a lack of consistent profitability and the potential for clinical trial failures due to drug toxicity.
Summary analytical data breakdowns for muraloncology.com (MURA)
- current price and projected stock value:
- company stock exchange capitalization indicators:
- business book valuation details:
- issuer credit burden and liquidity indicators:
Debt to Equity Mural Oncology plc|MURA - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Ratio Mural Oncology|MURA - Company Aggregate Debts|Debt to Book Capitalization Ratio MURA|MURA - Company Long-Term Loans and Borrowings|Company Short-Term Debts Mural Oncology|Quick Liquidity muraloncology.com
- business earnings and investment ratios data:
MURA - Company Net Income|Future Profit Mural Oncology plc|MURA - Company Value to Net Income|Future Price to Earnings Mural Oncology|MURA - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MURA|MURA - Operating profit before amortization|Net earnings per share (EPS TTM) Mural Oncology|MURA - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months muraloncology.com|MURA - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Mural Oncology plc
- company sales and revenue statistics:
Fundamental company analysis:MURA (Mural Bio)
The EV/EBITDA dynamics of Mural Oncology plc (MURA) reflect a synergy of operational efficiency and the oncology community's high level of confidence in the issuer's targeted interleukins. This ratio compares the total enterprise value with earnings before interest, taxes, depreciation, and amortization, making it possible to determine the maturity of assets and the investment margin of safety when assessing the fundamental stability of the growing scientific brand.
Key competitors
EV/EBITDA Multiple ONC (BeiGene Corp)|HALO - Enterprise Value to EBITDA Ratio|RVMD: Enterprise Value to EBITDA Ratio|AAPG - EV/EBITDA Multiple|CG Oncology (CGON) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|UroGen Pharma Ltd - Business Value to Operating Income Before Depreciation|BCAX (Bicara Bio) - EV/EBITDA Multiple|Company Value to EBITDA Personalis Genomics PSNL|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Erasca, Inc. (ERAS)|Enterprise Value to EBITDA Ratio delcath.com DCTH|Y-mAbs Therapeutics, Inc. - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Aura Biosciences Inc AURA|CADL - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation ARAY (Accuray, Inc.)|SLS: EV/EBITDA Multiple|actuatetherapeutics.com (ACTU) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Citius Oncology|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization HURA|Enterprise Value to EBITDA Ratio TARA (Protara)|FATE (Fate Pharma) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Aadi Bioscience WHWK|TScan Therapeutics Inc (TCRX) - Company Value to EBITDA|CSBR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|XBIT (XBiotech Inc.) - Enterprise Value to Operating Income Before Depreciation|CVM: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio OS Therapies, Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Radiopharm Theranostics|Company Value to EBITDA Artiva ARTV|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Adlai Nortye Ltd. (ANL)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization VERU (Veru Inc)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tempest Tx TPST|Xilio Therapeutics Inc (XLO) - Company Value to EBITDA|Enochian BioSciences - EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Kairos Pharma Ltd (KAPA)|OKUR (onkuretherapeutics.com) - Enterprise Value to EBITDA Ratio|Company Value to EBITDA CytoMed Therapeutics Limited (GDTC)|Enterprise Value to EBITDA Ratio CRIS|APLM: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tharimmune, Inc. (THAR)|ADVB: Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Genprex GNPX|Calidi Biotherapeutics Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Sunshine Biopharma - EV/EBITDA Multiple|Xenetic Biosciences (XBIO) - Enterprise Value to EBITDA Ratio|Salarius Pharmaceuticals (SLRX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio purple-biotech.com|Enterprise Value to EBITDA Ratio AONC|EV/EBITDA Multiple BeiGene Ltd.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Checkpoint Therapeutics, Inc (CKPT)|ELEV (Elevation Oncology Inc.) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ICAD (iCAD)|EV/EBITDA Multiple Ikena Oncology Inc. IKNA|Notable Labs - EV/EBITDA Multiple|Viracta Therapeutics (VIRX) - Enterprise Value to EBITDA Ratio|MOR: EV/EBITDA Multiple|NAYA Biosciences Corp (NAYA) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Ascentage Pharma Group
